Added to YB: 2026-08-31
Pitch date: 2026-08-28
303360.KQ [bullish]
Protia Inc.
Author Info
Numbers not Narrative digs into overlooked small and micro caps where the numbers tell a better story than the market does. Sign up for the newsletter.
Company Info
Protia Inc. manufactures and sells in vitro diagnostic medical devices in South Korea. It offers allergy, animal diagnosis, autoimmune, antibiotic susceptibility, POCT, cancer, and related instrument products, as well as protein analysis, LC-MS/MS, characterization analysis, and custom protein services.
Market Cap
KRW 62.9B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
9.55
P/E
11.49
EV/Sales
2.77
Sector
Health Care Equipment and Supplies
Category
growth
The Nespresso Model, Applied to Hospital Labs: Sell the Reader Once, Sell the Strips Forever - Protia Inc.
303360.KQ: PROTIA pairs patented, high-density allergy strips with proprietary readers installed at nine of Korea’s ten largest screening centres and contract labs, creating recurring consumables sales at minimal incremental allergen cost. Revenue grew 40% in the latest half and trailing operating margin reached 26.3%, yet the debt-free company trades at 10.7x trailing EV/EBIT and 8.3x estimated current-year EBIT. The discount reflects weak cash conversion, inventory reaching 386 days of sales and management’s preference for property over production investment.
Read full article (7 min)